Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This review reflects the presentations and discussion at the 14th post-American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single-cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR-ABL1 mutant subclones following ABL1-tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK-STAT and the merits of integrating activin receptor ligand traps, interferon-α, and allografting in the current treatment algorithm for patients with myelofibrosis.

Original publication

DOI

10.1002/hon.2771

Type

Journal article

Journal

Hematol Oncol

Publication Date

12/2020

Volume

38

Pages

654 - 664

Keywords

BCR-ABL1 mutants, genomic risk scores, interferon-alpha, luspatercept, non-JAK-STAT therapies, single-cell genomics, Anemia, Biomarkers, Biomarkers, Tumor, Combined Modality Therapy, Disease Management, Disease Susceptibility, Drug Development, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Molecular Diagnostic Techniques, Molecular Targeted Therapy, Myeloproliferative Disorders, Prognosis, Single-Cell Analysis, Translational Medical Research, Treatment Outcome